First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer (Q46972709)

27 December 2017

title

First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer (English)

1 reference

27 December 2017

1 reference

8

Erick Gamelin

1 reference

27 December 2017

Meinolf Karthaus

10

object named as

Meinolf Karthaus

1 reference

27 December 2017

author name string

Claus-Henning Köhne

1

1 reference

27 December 2017

Ralf Hofheinz

2

1 reference

27 December 2017

Laurent Mineur

3

1 reference

27 December 2017

Henry Letocha

4

1 reference

27 December 2017

Richard Greil

5

1 reference

27 December 2017

Josef Thaler

6

1 reference

27 December 2017

Eva Fernebro

7

1 reference

27 December 2017

Lucy Decosta

9

1 reference

27 December 2017

publication date

30 September 2011

1 reference

27 December 2017

Journal of Cancer Research and Clinical Oncology

published in

1 reference

27 December 2017

volume

138

1 reference

27 December 2017

issue

1

1 reference

27 December 2017

page(s)

65-72

1 reference

27 December 2017

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

Panitumumab the first fully human monoclonal antibody: from the bench to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1061-6

High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice

21 January 2018

1 reference

12 December 2020

Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone

1 reference

12 December 2020

Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage.

1 reference

12 December 2020

FDA narrows drug label usage

1 reference

12 December 2020

10.1007/S00432-011-1061-6

Identifiers

DOI

1 reference

27 December 2017

1 reference

27 December 2017